Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share, Analysis, Industry Report and Forecast 2020-2026
Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.3% over the forecast period (2020-2026). As per the International Diabetes Foundation IDF, around 59.3 million adults in the age range of 20-79 years are living with diabetes in the region in 2019. It represents around 8.9% of the regional population. The rising geriatric population in the region is a major factor for the increasing prevalence of type 2 diabetes in the region. Further, as per the IDF, it is also predicted that the prevalence of diabetes is likely to increase further to 66.0 million in 2030 and which will further reach more than 68.1 million in 2045. Such an increased prevalence of diabetes across the region creates a wide scope for market growth over the forecast period.
To Request a Sample of our Report on Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market: https://www.omrglobal.com/request-sample/europe-dipeptidyl-peptidase-4-inhibitors-market
However, there are severe side
effects associated with the use of the dipeptidyl peptidase 4 (DPP-4)
inhibitors for the treatment of lowering blood sugar levels in type 2 diabetic
patients. The continuous or long period usage of the dipeptidyl peptidase 4
(DPP-4) inhibitors might lead to headaches, nausea, skin reactions, heart
failure, nasopharyngitis, hypersensitivity, and even sometimes cancer. Hence,
such aforementioned factors directly impact the growth of the Europe dipeptidyl
peptidase 4 (DPP-4) inhibitors industry over the forecast period.
Market Coverage
·
Market number available for – 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Type
·
Regions Covered- Europe
·
Competitive Landscape- Boehringer Ingelheim
International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily &
Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, and Takeda
Pharmaceutical Co. among others
(Get 15% Discount on Buying this Report)
A full Report of Europe
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/europe-dipeptidyl-peptidase-4-inhibitors-market
By Type
·
Sitagliptin
·
Vildagliptin
·
Saxagliptin
·
Linagliptin
·
Gemigliptin
·
Anagliptin
·
Teneligliptin
·
Others
Europe Dipeptidyl
peptidase 4 (DPP-4) inhibitors Market – Countries Covered
·
UK
·
Germany
·
France
·
Italy
·
Spain
Rest of
Europe
Company
Profiles
·
AstraZeneca Plc
·
Boehringer Ingelheim International GmbH
·
Bristol Myers Squibb Co.
·
Eli Lily & Co.
·
GlaxoSmithKline Plc
·
LG Life Sciences Ltd.
·
Merck & Co.
·
Novartis AG
·
Pfizer Inc.
·
Sanofi SA
·
SatRx LLC
·
Takeda Pharmaceutical Co.
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/europe-dipeptidyl-peptidase-4-inhibitors-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment